UBS O'Connor’s Global Blood Therapeutics, Inc. GBT Stock Holding History

UBS O'Connor’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,238,787	Closed	-$152M	–	1032
2022 Q3	$152M	Buy	+2,238,787	New	+$123M	1.73%	11
2019 Q3	–	Sell	-35,800	Closed	-$1.88M	–	373
2019 Q2	$1.88M	Buy	+35,800	New	+$2.06M	0.04%	148
2016 Q3	–	Sell	-50,000	Closed	-$830K	–	518
2016 Q2	$830K	Buy	+50,000	New	+$1.01M	0.02%	323

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS O'Connor's GBT Position: Q4 2022 in Review

UBS O'Connor sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 2,238,787 shares — an estimated $152M sold.

UBS O'Connor first reported a position in GBT in Q2 2016 and held it in 3 quarters. The position peaked at $152M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

UBS O'Connor reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
UBS O'Connor sold 2,238,787 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $152M.
UBS O'Connor first reported a position in Global Blood Therapeutics, Inc. in Q2 2016 and held it in 3 quarters.
UBS O'Connor's Global Blood Therapeutics, Inc. position peaked at $152M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.